


Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age

Emilie Castermans,^{1,2*} Muriel Hannon,^{1,2*} Jacques Dutrieux,³ Stéphanie Humblet-Baron,² Laurence Seidel,⁴ Rémi Cheynier,³ Evelyne Willems,^{1,2} André Gothot,⁵ Jean-François Vanbellinghen,⁶ Vincent Geenen,⁷ Brenda M. Sandmaier,^{8,9} Rainer Storb,^{8,9} Yves Beguin,^{1,2} and Frédéric Baron^{1,2}


¹Department of Medicine, Division of Hematology, University and CHU of Liège, Liège, Belgium; ²GIGA Research-Hematology, University of Liège, Liège, Belgium; ³Department of Virology, Institut Pasteur, Paris, France; ⁴Department of Statistics, University of Liège, Liège, Belgium; ⁵Department of Laboratory Medicine, Division of Laboratory Hematology and Immuno-Hematology, University of Liège, Liège, Belgium; ⁶Department of Genetics, CHU of Liège, Liège, Belgium; Center of Immunology, University of Liège, Liège, Belgium; ⁸Fred Hutchinson Cancer Research Center, Seattle, WA, USA, and ⁹University of Washington, Seattle, WA, USA

Citation: Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, Willems E, Gothot A, Vanbellinghen J-F, Geenen V, Sandmaier BM, Storb R, Beguin Y, and Baron F. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. *Haematologica* 2011;96(2):298-306. doi:10.3324/haematol.2010.029702




Online Supplementary Figure S1. Evolution of sjTREC levels (A) and of naive CD4⁺ T-cell counts (B) in patients for which we had data on day 100 and one, two and three years after transplantation. The numbers indicate patient age at transplantation. Impact of graft manipulation (C) or on conditioning intensity on sjTREC levels and CD3⁺ T-cell and naive CD4⁺ T-cell counts after transplantation. DLI, donor lymphocyte infusion; 2 Gy TBI, 2 Gy total body irradiation with or without added fludarabine; 4 Gy TBI, 4 Gy TBI with fludarabine; FluCy, fludarabine with cyclophosphamide.


A. Normal controls



B. Low sjTREC levels



C. High sjTREC levels



[Online Supplementary Figure S2](#). Representative examples of TCRB repertoires in age-matched controls and in patients with low, intermediate or high sjTREC levels two to nine years after non-myeloablative HCT.

Online Supplementary Table S1. Patients' characteristics.

N=80	
Recipient median (range) age, years	57 (10-71)
Recipient sex: male / female	57 / 23
Donor median (range) age, years	42 (18-70)
Donor sex: male / female	48 / 32
Donor type	
HLA-identical sibling	33
1 Ag mismatched related donor	2
10/10 HLA allele matched unrelated donor	22
HLA-mismatched unrelated donor	23
1 single HLA-allele mismatch	5
≥ 1 single HLA-allele mismatch	18
Diagnosis, n. patients	
Acute myeloid leukemia	9
Myelodysplastic syndrome or myeloproliferative disorder	13
Chronic myeloid leukemia	1
Hodgkin's lymphoma	5
High-grade non-Hodgkin's lymphoma	9
Low-grade non-Hodgkin's lymphoma	12
Mantle cell lymphoma	4
Chronic lymphocytic leukemia	8
Multiple myeloma	18
Renal cell carcinoma	1
Conditioning regimen	
2 Gy TBI	20
2 Gy TBI + fludarabine (90 mg/m ²)	46
4 Gy TBI + fludarabine (90 mg/m ²)	6
Fludarabine (90 mg/m ²) + cyclophosphamide (3 g/m ²)	8
Stem cell source	
Unmanipulated PBSC	56
CD8-depleted PBSC	19
CD34-selected PBSC	5
Median (range) n. of cells infused (×10⁶/kg)	
CD34 ⁺ cells	4.5 (0.8-14.1)
CD3 ⁺ T cells	255 (0.04-1216)
Acute GVHD, n. patients	
Grade II	17
Grade III	3
Grade IV	0
Chronic GVHD, n. patients	
Limited	10
Extensive	34